Start here
Of the two redness creams I reach for this one first — different receptor than brimonidine, and rebound redness is reported less often. Less often is not never, so start cautiously: a test area for a few days, a small amount, once a day. You may recognize the ingredient from decongestant nasal sprays; the spray is not a face treatment. This buys a calmer looking day, not a cure — if you want the redness gone rather than paused, that conversation is about laser.
— Dr. Schwarz, Board Certified Dermatologist
Key Facts
−
| Also called | Rhofade, oxymetazoline hydrochloride 1% cream |
| Drug class | Alpha-1a adrenergic agonist, a blood vessel constrictor |
| Applied as | 1% cream |
| Typical course | Daily, for appearance |
| Time to work | Within about an hour, lasting most of the day |
| Prescription only | Yes |
What It Is
−
Oxymetazoline 1% cream is a prescription cream approved in 2017 for the persistent facial redness of rosacea in adults. You may know the molecule from decongestant nasal sprays, where it shrinks swollen vessels in the nose. The cream does the same to facial skin. It changes how red the skin looks while it is working. It does not treat inflammation or bumps, and it does not change the condition underneath.
How It Works
−
Rosacea's fixed redness comes from small facial vessels that stay wider than they should. Oxymetazoline is an alpha-1a adrenergic agonist. It makes the muscle in those vessel walls contract, so less blood sits near the surface and skin reads as less red. The effect starts within about an hour and in trials was still measurable at the end of a twelve-hour day.
The receptor difference from brimonidine is the point of the drug. Brimonidine acts on alpha-2 receptors, which sit in a feedback loop that can become less responsive to repeated stimulation — one proposed explanation for rebound redness. Alpha-1a receptors act more directly on the vessel wall.
Worsening redness and flushing are still reported with oxymetazoline, just less often. Lower risk, not no risk.
Here is where Oxymetazoline (Rhofade) acts in the skin.
About Oxymetazoline (Rhofade)
Skin basics
Oxymetazoline (Rhofade) tightens the widened vessels that make the skin look red. The colour fades for several hours and then returns: it treats how the skin looks that day and does nothing to the vessels themselves. The same idea as brimonidine, with less rebound reported.
Oxymetazoline crosses to the vessels in the dermis. Very little reaches the rest of the body from a cream.
The outer film of dead cells and oil. It holds water in and keeps irritants out, and it is thinner than a sheet of paper. Almost every dry, itchy, stinging skin problem starts here.
The outer layer, and the only one anything in a jar reaches. It renews itself constantly: a cell made at the bottom takes about a month to reach the surface and flake off. Most of what a skincare product does, it does here.
The living layer underneath, holding the blood vessels, the nerves and the collagen. It is where lasting change happens and it is hard to reach: most of what is sold for the skin never gets this far.
What It Treats
−

Not the Best For
−
Forms
−
One prescription form for the face.
1% cream:
Decongestant nasal spray:
Strengths
−
One strength only.
Basics
−
Sample Routine
−
Here is where Oxymetazoline (Rhofade) sits in a day, and what goes around it. Pick what you are treating and what your skin is like, and the rest of the routine changes to suit.
What to Expect
−
What to Avoid
−
- More than a pea-sized amount Or twice a day. Once daily is the maximum; more cream does not buy more effect.
- Eyes, eyelids, lips and inside the nose Keep it to facial skin. Rinse with water if it gets in the eyes.
- Using a decongestant nasal spray instead Same ingredient, different concentration, a base made for the nose. Not a substitute.
- Broken, raw or sunburned skin More is absorbed and it stings.
- Leaving it where a child can reach it Swallowing this ingredient can make a small child seriously unwell.
- Dropping your bump treatment The face looks calmer, but this does nothing for papules or pustules. The other medicine still has a job.
Monitoring
−
No routine blood tests. Monitoring is visual — does the redness reduce, does it worsen, does your skin tolerate the cream.
A small amount is absorbed, so the class effects — lower blood pressure, a slow heart rate, dizziness — are theoretically possible. They are rare on intact skin, but they are why heart problems, low blood pressure, circulatory disease and certain psychiatric medicines are worth raising first.
Review a few weeks in, and the only question is whether the result justifies continuing.
If You Stop
−
No taper, nothing to withdraw from. Redness returns to its usual level within a day; the cream was holding the vessels narrowed, not changing them. For the few people who stop because redness or flushing got worse, it settles back to baseline over days to a couple of weeks. A plain moisturizer and a pause on other active products is the usual advice. Because there is no cumulative benefit, some use it only on the days they want it. Reasonable to discuss with your doctor.
Cost
−
Brand priced, and coverage is inconsistent because insurers often treat facial redness as cosmetic. Prior authorization is common. A pump lasts a while if you stick to the pea-sized rule. Manufacturer savings offers exist and change often. Where cost rules it out, price generic brimonidine gel where available, green-tinted makeup, and — if you want a lasting change rather than a daily one — laser or light treatment.
Ask Your Doctor
−
How It Compares
−
Myths
+
- "It is the same as putting nasal spray on your face." The ingredient is shared; the products are not interchangeable. The cream is formulated and dosed for facial skin. The spray is not.
- "It cures rosacea." It changes color for the day. Stopping returns the skin to where it was.
- "It treats the bumps as well as the redness." It does not. Papules and pustules need ivermectin, azelaic acid, metronidazole or an oral treatment.
- "It cannot cause rebound because it is not brimonidine." Worsening redness and flushing are reported less often, but still reported. Lower risk is not no risk.
- "Twice a day would work better." Once daily is the maximum studied and advised. More cream does not buy more effect.
Questions Patients Ask
+
How is this different from brimonidine gel?
Both narrow facial vessels, through different receptors. Brimonidine works faster and wears off sooner; oxymetazoline covers more of a working day and rebound redness is reported less often. Neither treats the condition.
Can I use decongestant nasal spray on my face instead, since it has the same ingredient?
No. Different concentration, different base, different intended surface. It is not a cheaper version of this medicine.
Will it help my bumps and pustules?
No. Blood vessels only. Bumps need their own treatment, and the two are often used together.
Will it stop me flushing when I drink wine or eat something spicy?
Not reliably. It reduces fixed background redness. Flushing is a faster, different response, and some people report more of it on this cream.
How long before I know whether it works?
A single application shows the same day. Give it a few weeks to judge whether it is worth continuing.
Can I wear sunscreen and makeup over it?
Yes, once it has dried. Keep the daily sunscreen either way — sun is a common rosacea trigger.
References
+
- Clanner-Engelshofen BM, Bernhard D, Dargatz S, et al. S2k guideline: Rosacea. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2022. — Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022
- Liu F, Zhou Q, Wang H, et al. Efficacy and safety of oxymetazoline for the treatment of rosacea: A meta-analysis. Journal of cosmetic dermatology. 2023. — Journal of cosmetic dermatology, 2023
- van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. The British journal of dermatology. 2019. — The British journal of dermatology, 2019
- Gao X, Xiang W. Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis. Actas dermo-sifiliograficas. 2025. — Actas dermo-sifiliograficas, 2025
- Nguyen L, Sorbe C, Seeber N, et al. Laser and energy-based devices for treating rosacea - a systematic review and network meta-analysis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2026. — Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026
